The impact of blood glucose control on the degree of required medical interventions and mortality in patients with COVID-19 and T2DM remains uncertain. A recent retrospective study involving 7337 patients with COVID-19, among which 952 cases had pre-existing T2DM, demonstrated that T2DM was associated with higher mortality and multiple organ injury as compared to non-diabetic individuals. Additionally, glycaemic variability within 3.9 to 10.0mmol/L was associated with markedly lower mortality as compared to individuals with upper limit of glycaemic variability exceeding 10.0mmol/L. The findings highlight the importance of glycaemic control for patients with COVID-19.

Keywords: blood glucose, glycaemic control, COVID-19, T2DM

References

1. Zhu et al, 2020. Cell Metabolism, 31; 1-10

2. Bornstein et al, 2020. Lancet Diabetes Endocrinol, published online, April 23, 2020